Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-04 04:40:41 - browse：988

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

WSS

How to save health care price transparency rules

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Pushing for an NIH office for post

BMI, flaws aside, is found to be useful estimate of body fat in youth

NIH documents show early flaws of $1.6 billion long Covid program

Wikipedia

Wikipedia

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Activists slam private health insurers over coverage restrictions

Readout Newsletter: Bristol, Sangamo, Gilead, and more

After affirmative action ruling, medical educators look to 'holistic review'

WuXi out of biotech trade group, U.S. and China relations to blame

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare coverage of Wegovy, once blocked, now looks possible

In Memoriam: Notable people who died in 2023

FDA's Pazdur wants cancer trials to range beyond China alone

hotspot

Kaiser's Risant Health gobbled up Geisinger. Who is next?

HIV drugs protect against transmission, even in unprotected sex

FDA advisers back CAR

Change Healthcare can notify patients about the breach, HHS says

Letters to First Opinion on caregivers, digital health, and more

ASCO: AstraZeneca says CAR

leisure time

hotspot

focus

focus